Literature DB >> 2836522

Antigenic and immunogenic properties of a hepatitis A virus capsid protein expressed in Escherichia coli.

J M Johnston1, S A Harmon, L N Binn, O C Richards, E Ehrenfeld, D F Summers.   

Abstract

We have constructed a recombinant plasmid producing, in bacteria, a hepatitis A virus (HAV) capsid protein that may be useful as a subunit vaccine. HAV VP1 coding sequences were fused in-frame to NH2-terminal Escherichia coli TrpE coding sequences under the control of the tryptophan promoter. In the absence of exogenous tryptophan, E. coli containing this recombinant plasmid produced high levels of an 88-kilodalton fusion protein that was recognized in immunoblots by antibodies to TrpE and HAV. The TrpE/HAV VP1 protein was gel-purified and used to immunize rabbits. The resulting antiserum reacted with denatured HAV VP1 in immunoblots but did not react with intact virus. However, subsequent inoculation of an immunized animal with a subimmunogenic dose of inactivated, whole HAV resulted in the rapid appearance of a stable, virus-neutralizing antibody response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836522     DOI: 10.1093/infdis/157.6.1203

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus.

Authors:  L H Ping; R W Jansen; J T Stapleton; J I Cohen; S M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

2.  Replication of hepatitis A viruses with chimeric 5' nontranslated regions.

Authors:  X Y Jia; M Tesar; D F Summers; E Ehrenfeld
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 3.  Prophylactic treatment regimens for the prevention of hepatitis A. Current concepts.

Authors:  B J Kendall; W G Cooksley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

4.  The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles.

Authors:  P L Winokur; J H McLinden; J T Stapleton
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Recombinant vaccinia viruses expressing hepatitis A virus structural polypeptides: detection of an anti-VP0 response in convalescent-phase sera.

Authors:  P Karayiannis; S O'Rourke; R Watts; J Waters; V Hill; W F Carman; H C Thomas
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

6.  Immunologic priming with recombinant hepatitis A virus capsid proteins produced in Escherichia coli.

Authors:  T F Powdrill; J M Johnston
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

7.  Recombinant hepatitis A virus antigen: improved production and utility in diagnostic immunoassays.

Authors:  F D LaBrecque; D R LaBrecque; D Klinzman; S Perlman; J B Cederna; P L Winokur; J Q Han; J T Stapleton
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

8.  Solubility as a limiting factor for expression of hepatitis A virus proteins in insect cell-baculovirus system.

Authors:  Haroldo Cid da Silva; Cristiane Pinheiro Pestana; Ricardo Galler; Marco Alberto Medeiros
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-07-11       Impact factor: 2.743

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.